STAR · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 55/100 — Quality 59 · Valuation 37 · Momentum 75
| Share price | ₹1,059.50 |
| Market cap | ₹9,979 Cr |
| P/E ratio | 18.0 |
| P/B ratio | 3.2 |
| ROCE | 21.0% |
| Dividend yield | 0.37% |
| Book value | ₹337.09 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹4,859 Cr | ₹575 Cr | 19.0% |
| 2025 | ₹4,565 Cr | ₹3,598 Cr | 18.0% |
| 2024 | ₹3,890 Cr | ₹-94 Cr | 14.0% |
| 2023 | ₹3,688 Cr | ₹-212 Cr | 4.0% |
| 2022 | ₹3,070 Cr | ₹-474 Cr | -4.0% |
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer